CN115005447A - Application of oligoguluronic acid in preparation of anti-fatigue product - Google Patents
Application of oligoguluronic acid in preparation of anti-fatigue product Download PDFInfo
- Publication number
- CN115005447A CN115005447A CN202210680622.8A CN202210680622A CN115005447A CN 115005447 A CN115005447 A CN 115005447A CN 202210680622 A CN202210680622 A CN 202210680622A CN 115005447 A CN115005447 A CN 115005447A
- Authority
- CN
- China
- Prior art keywords
- fatigue
- acid
- product
- products
- oligoguluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 title claims abstract description 19
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229920002527 Glycogen Polymers 0.000 claims abstract description 21
- 229940096919 glycogen Drugs 0.000 claims abstract description 21
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 15
- 239000004310 lactic acid Substances 0.000 claims abstract description 15
- 210000003205 muscle Anatomy 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 238000011084 recovery Methods 0.000 claims abstract description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004202 carbamide Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 5
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- -1 oligosaccharide compound Chemical class 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009182 swimming Effects 0.000 description 26
- 206010016256 fatigue Diseases 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 description 7
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 159000000003 magnesium salts Chemical class 0.000 description 5
- 229960002666 1-octacosanol Drugs 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000968420 Dynamena pumila Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of oligoguluronic acid in preparing an anti-fatigue product, wherein the product comprises the following components in parts by weight: (1) products that increase exercise tolerance of skeletal muscle; (2) a product for accelerating the fatigue recovery of the organism; (3) an anti-fatigue product; (4) products for reducing the content of lactic acid and urea in serum after exercise; or (5) products that increase the body's liver glycogen and muscle glycogen stores.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to application of oligoguluronic acid in preparation of an anti-fatigue product.
Background
Fatigue is a complex physiological and biochemical change process of an organism, and refers to a normal physiological phenomenon which is necessarily caused when mental or physical strength reaches a certain stage. It marks a temporary decline in the body's original working capacity and may be a precursor to the body's development of a disease state. The occurrence of fatigue can cause reduced exercise capacity, reduced work efficiency, and increased error accidents. If the fatigue can not be recovered in time after the occurrence of fatigue, the fatigue can be gradually accumulated, so that endocrine disturbance and immunity decline of the organism can be caused, even organic diseases can be caused, and the health of human beings can be threatened.
The fatigue of the body can be eliminated by rest, sleep and physical methods, and the anti-fatigue effect can be realized by supplementing nutrient substances and medication. Some Branched Chain Amino Acids (BCAA) including leucine and isoleucine are decomposed and metabolized in muscles, are easily oxidized to provide energy for organisms, and have important effects on maintaining normal activities of human brains and delaying and eliminating exercise-induced fatigue. In addition, creatine, B vitamins, vitamin C, vitamin E, vitamin A, carotene, trace elements of selenium, copper, zinc, metallothionein and the like can also improve the metabolism of the organism and delay the occurrence of fatigue. In recent years, fatigue has attracted more and more attention as a sub-health symptom, and anti-fatigue, i.e., delaying the generation of fatigue and/or promoting the elimination of fatigue, has become a hot issue of research in sports medicine.
The Guluronic acid oligosaccharide is intercellular polysaccharide extracted from marine brown algae, and is a linear compound formed by connecting L-Guluronic acid (L-Guluronic acid, G) through alpha-1, 4-glycosidic bond. At present, the polyguluronic acid has a plurality of biological activities such as oxidation resistance, immunoregulation and mucosal protein function regulation reported in domestic and foreign documents, but no report is found about the research and application of the polyguluronic acid in the aspect of fatigue resistance.
Disclosure of Invention
The invention firstly relates to the use of oligoguluronic acids or salts thereof for producing:
(1) products that increase exercise tolerance of skeletal muscle;
(2) a product for accelerating the fatigue recovery of the organism;
(3) an anti-fatigue product;
(4) products for reducing the content of lactic acid and urea in serum after exercise;
(5) products that increase the body's liver glycogen and muscle glycogen stores;
the product is a food or a medicine,
the structure of the oligoguluronic acid or the salt thereof is shown as the following formula, the molecular skeleton is a linear oligosaccharide compound formed by connecting L-guluronic acid (G) through alpha- (1,4) -glycosidic bonds, and the weight average molecular weight range is 0.3 kD-15 kD;
wherein, R is H or Li, Na, K, Ca, Mg, n is less than or equal to 60.
The food or the medicine is an oral dosage form, including but not limited to tablets, granules and oral liquid;
the food or the medicine comprises an effective amount of the oligoguluronic acid or the salt thereof and necessary auxiliary materials.
The beneficial effect of the invention is that,
(1) the invention demonstrates that the oligoguluronic acid can better increase the exercise tolerance of skeletal muscle, accelerate the recovery of tired organism and has good anti-fatigue effect.
(2) The guluronic acid oligosaccharide compound provided by the invention has the advantages of low molecular weight acid oligosaccharide, is strong in water solubility, easy to absorb, rich in source, unique in action mechanism and wide in industrial development and application prospect.
Drawings
FIG. 1, chemical structure of low molecular weight guluronic acid (LG) (salt).
Detailed Description
Experiments show that the low molecular weight guluronic acid can effectively prolong the swimming time of the exhausted mouse, obviously reduce the levels of blood lactic acid and serum urea nitrogen, and obviously improve the contents of liver glycogen and muscle glycogen of the exhausted mouse for the first time; therefore, it can be used for preventing or improving fatigue symptoms.
The low molecular weight guluronic acid in the invention can be obtained by grading and degrading algin extracted from kelp, sea oak, Ascophyllum nodosum, kelp or brown algae related to Chordannia, or by chemical synthesis.
The sugar residues of the low molecular weight guluronic acid (LG) are all composed of alpha-1, 4-D-mannuronic acid, and the structural formula is as follows:
wherein R is H or metal cations such as Li, Na, K, Ca, Mg and the like, n is less than or equal to 80, and preferably 25 to 50;
the weight average molecular weight of the low molecular weight guluronic acid is in the range of 0.3kD to 15kD, preferably 5kD to 10 kD.
Example 1: effect of oligoguluronic acid (LG) on exhaustion of mouse swimming time
The duration of the mouse from continuous movement to exhaustion can be measured to reflect the endurance of the body.
The experimental steps of the mouse swimming exhaustion model are as follows:
(1) the mice were continuously gavage for 2 weeks, and the gavage drugs and the doses were as follows: the positive drug is octacosanol (10mg/kg), the oligoguluronate is a low dose group (25mg/kg), a medium dose group (50mg/kg) and a high dose group (100 mg/kg); gavage is performed 1 time per day; the salt form of LG is sodium salt or magnesium salt, and the weight average molecular weight is 8 kD.
(2) After half an hour of the last treatment, the lead wires with the weight of 3 percent loaded on the tail of the mouse are placed in a swimming pool with the water temperature of 30 +/-1 ℃ and the swimming time of the mouse, namely the swimming exhaustion time of the mouse, from the beginning of swimming to the time when the mouse sinks 8 seconds below the water surface without power and can not float out of the water surface, is recorded.
The results are shown in table 1: the exhaustive swimming time and the LG have a linear dose effect relationship, the exhaustive swimming time of the high-dose group is increased by 63.5 percent, the exhaustive swimming time of the medium-dose group is increased by 39.2 percent and the exhaustive swimming time of the octacosanol group is increased by 67.5 percent relative to the blank group, which shows that the movement endurance of mice can be improved by the LG high-dose group and the LG medium-dose group, so that the magnesium salt has an anti-fatigue effect, and the magnesium salt has a more ideal effect compared with the sodium salt.
TABLE 1 Effect of LG on mouse weight bearing swimming time
P <0.01 (compared to model group) and p <0.05 (compared to model group).
Example 2: effect of oligoguluronic acid (LG) on depleting mouse Blood Lactic Acid (BLA) and serum urea nitrogen (BUN)
The appearance and progression of fatigue can be observed, usually by measuring biochemical indicators that cause fatigue. When the mouse body can not obtain enough energy through sugar and fat catabolism for a long time, protein and amino acid catabolism is strengthened, nucleotide metabolism is accelerated, and the final products of the metabolic pathway generate urea. The less production of haematurin, the stronger the body endurance of the mouse and the more capable it is to bear the exercise load.
Blood lactic acid is a product of glycolysis under an anoxic condition, and along with the acceleration of glycolysis speed, the content of lactic acid in muscles is continuously accumulated, so that the pH value of cells is reduced, a series of biochemical changes are generated, and further fatigue is caused. The more lactic acid accumulates in the muscle, the more severe the fatigue manifests itself.
The experimental steps of the mouse swimming exhaustion model are as follows:
(1) after 2 weeks of continuous gavage, the positive drug is octacosanol (10mg/kg), the oligoguluronate is in a low dose group (25mg/kg), a medium dose group (50mg/kg) and a high dose group (100 mg/kg); gavage is performed 1 time per day; the salt type of LG is magnesium salt, and the weight average molecular weight is 8 kD.
(2) After half an hour of the last treatment, taking blood from tail veins, measuring the content of Blood Urea Nitrogen (BUN) and Blood Lactic Acid (BLA) before swimming, putting lead wires with 3 percent of weight of mouse tail into a 50 x 40 swimming pool for swimming, keeping the water temperature at 30 +/-1 ℃, taking out the mouse after swimming for 1 hour, and removing the weight;
(3) blood is collected from eyeball 15min after resting, and Blood Urea Nitrogen (BUN) and Blood Lactic Acid (BLA) content of mouse are determined.
The results are shown in table 2, and it can be seen that,
(1) before swimming, the difference of the serum urea nitrogen of each group is not obvious, and after swimming, the serum urea nitrogen content of each group is obviously increased. After swimming, the mid-and high-dose groups of LG and the octacosanol group serum urea nitrogen were significantly lower than the model group, suggesting that LG reduces serum urea nitrogen accumulation in sports mice.
(2) The blood lactic acid content difference of each group before swimming is not obvious, and the blood lactic acid content of each group after swimming is obviously increased. And the blood lactic acid content of the model group is obviously higher than that of the high-dose group and octacosanol group of LG, which shows that LG can reduce blood lactic acid accumulation in a mouse body after exercise and accelerate the recovery of the body.
TABLE 2 Effect of LG on mouse serum Urea Nitrogen (BUN) and Blood Lactic Acid (BLA)
P <0.05 (compared to model group).
Example 3: effect of oligoguluronic acid (LG) on liver glycogen and myoglycogen in depleted mice
Glycogen stores in organisms are positively correlated with exercise tolerance. When the exercise time is increased, a large amount of muscle glycogen is consumed, the exercise capacity of the organism is reduced, fatigue occurs, the intake amount of blood sugar is increased, and when the intake rate is higher than the decomposition rate of liver glycogen, the blood sugar level is reduced. Because blood glucose supplies the central nervous system, a decrease in blood glucose can cause an under-motivation of the central nervous system, resulting in systemic fatigue.
The experimental steps of the mouse swimming exhaustion model are as follows:
(1) after 2 weeks of continuous gavage of the mice, the positive drug is octacosanol (10mg/kg), the oligoguluronate is a low dose group (25mg/kg), a medium dose group (50mg/kg) and a high dose group (100 mg/kg); gavage is performed 1 time per day; the salt form of LG is magnesium salt, and the weight average molecular weight is 8 kD.
(2) After half an hour of the last treatment, putting the lead wire with the weight of 3 percent loaded at the tail of the mouse into a swimming pool of 50 multiplied by 40 for swimming, wherein the water temperature is 30 +/-1 ℃, taking out the mouse after 1 hour of swimming, and removing the load;
(3) after blood was taken from the eyeball, the eyeball was immediately sacrificed, and the liver and hind leg muscles were taken out and the liver glycogen and muscle glycogen content were measured, respectively.
The results are shown in Table 3 and show that: the liver glycogen and muscle glycogen of the medium-high dose group and the octacosanol group are obviously higher than those of the blank group, and the LG of the medium-high dose group can increase the liver glycogen and muscle glycogen content, and the glycogen can be directly decomposed into glucose to enter blood to be utilized by other tissues through blood circulation. Therefore, LG in the medium and high dose groups can delay and resist the onset of fatigue.
TABLE 3 Effect of LG on mouse liver glycogen and muscle glycogen
P <0.05 (compared to model group), p <0.01 (compared to model group); # p <0.05 (compared to positive drug).
The experimental results show that the oligoguluronic acid can better increase the exercise tolerance of skeletal muscle and accelerate the recovery and anti-fatigue effects of a fatigue organism. The oligoguluronic acid can be used as a natural health product or medicine for preventing and treating fatigue. The product is derived from marine algae, has the advantages of abundant resources, easy industrialization, high safety and the like, and has wide market and application prospects in the aspect of fatigue resistance. The invention provides reference meaning and inspiration for high-value utilization of marine algae.
Finally, it should be noted that the above embodiments are only used to help those skilled in the art understand the essence of the present invention, and are not used to limit the protection scope of the present invention.
Claims (4)
1. Use of oligoguluronic acid or a salt thereof for the preparation of:
(1) products that increase exercise tolerance of skeletal muscle;
(2) a product for accelerating the fatigue recovery of the organism;
(3) an anti-fatigue product;
(4) products for reducing the content of lactic acid and urea in serum after exercise;
(5) products that increase the body's liver glycogen and muscle glycogen stores;
the product is food or medicine.
2. The use according to claim 1, wherein the oligoguluronic acid or the salt thereof has a structure represented by the following formula, wherein the molecular skeleton is a linear oligosaccharide compound formed by connecting L-guluronic acid (G) through an alpha- (1,4) -glycosidic bond, and the weight average molecular weight is 0.3-15 kD; preferably 5-10 kD;
in the formula, R is H or Li, Na, K, Ca and Mg, preferably Mg, and n is less than or equal to 75, preferably 25-50.
3. The use according to claim 1 or 2, wherein the food or pharmaceutical product is in an oral dosage form, including but not limited to tablets, granules, oral liquid.
4. Use according to claim 1 or 2, characterized in that said food or pharmaceutical product comprises an effective amount of said oligoguluronic acid or a salt thereof, and the necessary excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210680622.8A CN115005447B (en) | 2022-06-16 | 2022-06-16 | Application of oligoguluronic acid in preparation of anti-fatigue product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210680622.8A CN115005447B (en) | 2022-06-16 | 2022-06-16 | Application of oligoguluronic acid in preparation of anti-fatigue product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115005447A true CN115005447A (en) | 2022-09-06 |
| CN115005447B CN115005447B (en) | 2024-02-06 |
Family
ID=83075441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210680622.8A Active CN115005447B (en) | 2022-06-16 | 2022-06-16 | Application of oligoguluronic acid in preparation of anti-fatigue product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115005447B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137723A1 (en) * | 2000-02-03 | 2002-09-26 | Byon Jae Hyong | Low molecular weight polymannuronate |
| CN1518897A (en) * | 2003-09-01 | 2004-08-11 | 中国海洋大学 | Combined holoside as well as preparation method and application |
| CN101325973A (en) * | 2005-10-06 | 2008-12-17 | Ntnu技术转让公司 | Use of oligouronates for treating mucus hyperviscosity |
| US20110177132A1 (en) * | 2008-05-23 | 2011-07-21 | Aliza Apple Allon | Compositions and Methods for Generating Musculoskeletal Tissue |
| CN103948611A (en) * | 2014-03-31 | 2014-07-30 | 青岛海洋生物医药研究院股份有限公司 | Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products |
| CN104666327A (en) * | 2015-01-14 | 2015-06-03 | 中国海洋大学 | Application of low-polymer mannuronic acid and derivative thereof in preparation of medicines and health products for resisting fatigue and amyotrophia |
| CN105395563A (en) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof |
| CN110652517A (en) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | Algin oligosacchride diacid composition |
-
2022
- 2022-06-16 CN CN202210680622.8A patent/CN115005447B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137723A1 (en) * | 2000-02-03 | 2002-09-26 | Byon Jae Hyong | Low molecular weight polymannuronate |
| CN1518897A (en) * | 2003-09-01 | 2004-08-11 | 中国海洋大学 | Combined holoside as well as preparation method and application |
| CN101325973A (en) * | 2005-10-06 | 2008-12-17 | Ntnu技术转让公司 | Use of oligouronates for treating mucus hyperviscosity |
| US20110177132A1 (en) * | 2008-05-23 | 2011-07-21 | Aliza Apple Allon | Compositions and Methods for Generating Musculoskeletal Tissue |
| CN103948611A (en) * | 2014-03-31 | 2014-07-30 | 青岛海洋生物医药研究院股份有限公司 | Application of oligomeric guluronic acid salts in preparation of Parkinson's disease prevention and treatment drugs or products |
| CN104666327A (en) * | 2015-01-14 | 2015-06-03 | 中国海洋大学 | Application of low-polymer mannuronic acid and derivative thereof in preparation of medicines and health products for resisting fatigue and amyotrophia |
| CN105395563A (en) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | Application of oligoguluronic acid and derivative thereof in preparation of drugs and health products used for preventing and treating hyperlipidemia and complications thereof |
| CN110652517A (en) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | Algin oligosacchride diacid composition |
| US20210260085A1 (en) * | 2018-06-29 | 2021-08-26 | Shanghai Green Valley Pharmaceutical Co., Ltd. | Composition of alginic oligosaccharic diacids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115005447B (en) | 2024-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100502692C (en) | Physical recovery healthy food and preparation process thereof | |
| CN102960808B (en) | Alcohol-alleviating anti-fatigue beverage | |
| CN101889679B (en) | Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food | |
| CN102448452A (en) | Dietary supplement comprising alpha keto acids for supporting diabetes therapy | |
| CN102090692A (en) | Oyster polypeptide anti-fatigue beverage and preparation method thereof | |
| CN103251054B (en) | Anti-fatigue health protection food composition and preparation method thereof | |
| CN1742605A (en) | Soy-bean peptide | |
| CN103371317A (en) | Ribose functional food | |
| CN107164446A (en) | The preparation method and its antifatigue effect of deer hemepeptide | |
| CN1535605A (en) | Drink and food | |
| CN101273775A (en) | Cordyceps mycelium capsules and producing process thereof | |
| US20230364042A1 (en) | Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses | |
| CN104666327B (en) | The application of oligomannuronic acid and its derivative in the medicine and health products for preparing antifatigue and anti-amyotrophia | |
| CN101352236B (en) | Big fruit sea-buckthorn compound fatigue-resistant powder and preparation method thereof | |
| CN115005447B (en) | Application of oligoguluronic acid in preparation of anti-fatigue product | |
| JP6710098B2 (en) | Nutritional composition and dietary supplement | |
| CN107325163B (en) | Astragalus seed protein and application thereof in anti-sports fatigue functional food | |
| CN103330118A (en) | Antiobesity drug | |
| CN101336723A (en) | Health food for relieving physical fatigue | |
| CN102631503A (en) | Antifatigue traditional Chinese medicine composition and preparation method thereof | |
| CN101032562A (en) | Health care product having functions of conditioning blood pressure and protecting haemal system of heart and brain | |
| WO2005041949A1 (en) | Composition for the treatment of dysfunctional energy metabolism syndrome | |
| US8609165B1 (en) | Dietary supplement for optimizing glucose levels, increasing energy, and improving general health | |
| CN1861099B (en) | Snake oil soft capsule | |
| AU2021104139A4 (en) | Nadh composition for improving exercise endurance and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |